Why This Matters for Your Career
Novartis is hiring 10 roles related to this product
ALLOPURINOL (allopurinol) by Novartis is xanthine oxidase inhibitors [moa]. Approved for symptoms of primary, secondary gout (acute attacks, tophi and 15 more indications. First approved in 2022.
Xanthine Oxidase Inhibitors
Xanthine Oxidase Inhibitor
Worked on ALLOPURINOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
Evaluation of PK and Safety of D-0120 and Allopurinol
A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol
Novartis is hiring 10 roles related to this product